XL Etanercept in the treatment of plaque psoriasis

被引：0
作者：
Nguyen, Thao U. [1 ]
Koo, John [1 ]
机构：
[1] Univ Calif San Francisco, Psoriasis & Skin Treatment Ctr, Dept Dermatol, 515 Spruce St, San Francisco, CA 94143 USA
来源：
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2009年 / 2卷
关键词：
etanercept; plaque psoriasis; tumor necrosis factor antagonist;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Etanercept is approved for the treatment of moderate to severe plaque psoriasis at a dose of 50 mg twice weekly for 3 months followed by a maintenance dosage of 50 mg weekly thereafter. Clinical studies have shown excellent efficacy, favorable benefit to side-effects ratio, and safe long-term usage. Extensive information on safety is available as etanercept has been used for many years for other indications such as rheumatoid arthritis and psoriatic arthritis and is the first of the tumor necrosis factor antagonists to gain approval in psoriasis.
引用
收藏
页码：77 / 84
页数：8
相关论文
共 74 条
[61]  
Strober Bruce E, 2004, J Drugs Dermatol, V3, P270
[62]  
The Food and Drug Administration, 2008, EARL COMM ONG SAF RE
[63]   Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial [J].
Tyring, S ;
Gottlieb, A ;
Papp, K ;
Gordon, K ;
Leonardi, C ;
Wang, A ;
Lalla, D ;
Woolley, M ;
Jahreis, A ;
Zitnik, R ;
Cella, D ;
Krishnan, R .
LANCET, 2006, 367 (9504) :29-35
[64]   Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis [J].
Tyring, Stephen ;
Gordon, Kenneth B. ;
Poulin, Yves ;
Langley, Richard G. ;
Gottlieb, Alice B. ;
Dunn, Meleana ;
Jahreis, Angelika .
ARCHIVES OF DERMATOLOGY, 2007, 143 (06) :719-726
[65]   Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension [J].
van de Kerkhof, P. C. M. ;
Segaert, S. ;
Lahfa, M. ;
Luger, T. A. ;
Karolyi, Z. ;
Kaszuba, A. ;
Leigheb, G. ;
Camacho, F. M. ;
Forsea, D. ;
Zang, C. ;
Boussuge, M. P. ;
Paolozzi, L. ;
Wajdula, J. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (05) :1177-1185
[66]  
Wu Y, 2008, J DRUGS DERMATOL, V7, P373
[67]  
*WYETH EUR LTD, 2005, ENBR SUMM PROD CHAR
[68]   The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy [J].
Zachariae, Claus ;
Mork, Nils-Jorgen ;
Reunala, Timo ;
Lorentzen, Henrik ;
Falk, Edvard ;
Karvonen, Seija-Liisa ;
Johannesson, Anders ;
Clareus, Birgitta ;
Skov, Lone ;
Mork, Gro ;
Walker, Sian ;
Qvitzau, Susanne .
ACTA DERMATO-VENEREOLOGICA, 2008, 88 (05) :495-501
[69]   Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study [J].
Zein, NN .
JOURNAL OF HEPATOLOGY, 2005, 42 (03) :315-322
[70]  
Zhou H, 2004, INT J CLIN PHARM TH, V42, P267
12345678